Issue 25-4, 2026

Review

https://doi.org/10.38025/2078-1962-2026-25-4-105-113

Clinical and Physiological Rationale and Methodology for the Use of Medical Xenon in the Complex Treatment of Pain Syndrome in Osteoarthritis: A Review

View article (Download PDF file)



Download XML file

ORCIDElena A. Shomina*, ORCIDVladimir V. Guriev, ORCIDNikolay V. Yarygin

Russian University of Medicine, Moscow, Russia


ABSTRACT

INTRODUCTION. This review presents an in-depth analysis of the use of medical xenon as a universal agent in modern anesthesiology and therapeutic practice. Particular attention is paid to the use of xenon for the management of chronic pain syndrome in osteoarthritis, where adverse effects and insufficient analgesic efficacy often limit traditional pharmacotherapy. A high safety profile, the absence of systemic toxicity, and the ability to modulate central sensitization make this inert gas a promising component of multimodal analgesia.

AIM.To analyze the clinical application of medical xenon and substantiate its efficacy and safety in the treatment of pain syndrome in patients with osteoarthritis based on a systematic review of the literature.

MAIN CONTENT OF THE REVIEW. This review was prepared through a systematic search and critical analysis of international literature focusing on the physicochemical properties, pharmacodynamics of medical xenon, and its clinical application in anesthesiology and the management of pain syndromes in osteoarthritis. Relevant publications were identified in Russian and international databases, including eLIBRARY.RU, PubMed, Scopus, and Google Scholar. The search period covered studies from the earliest fundamental research on inert gases (1898) to contemporary clinical guidelines and multicenter trials (2025). The paper examines the physicochemical determinants and molecular mechanisms of action of this inert gas, including its effects on NMDA receptors and metabotropic complexes. The stages of xenon anesthesia are described in detail, and its high safety profile in geriatric and pediatric populations is substantiated. Particular attention is given to an innovative method for managing pain syndromes in patients with osteoarthritis through local para-articular injections of highly purified xenon. The presented clinical experience demonstrates a significant reduction in pain intensity according to the Visual Analog Scale (VAS), along with prolonged analgesic effects in the absence of systemic toxicity. The use of specialized equipment enables optimization of dosing regimens and minimization of adverse effects, thereby opening broad prospects for the use of xenon therapy in the rehabilitation of patients with degenerative joint diseases and in reducing disability rates.

CONCLUSION. Available data suggest that xenon can be considered a promising component of multimodal analgesia in patients with osteoarthritis. However, further randomized controlled trials specifically focused on this patient population are required, particularly to assess long-term efficacy and the impact on the neuropathic component of pain.


KEYWORDS: medical xenon, xenon therapy, osteoarthritis, analgesia, NMDA receptors, para-articular injections, pain syndrome, general anesthesia, cognitive safety, noble gases

FOR CITATION: Shomina E.A., Guriev V.V., Yarygin N.V. Clinical and Physiological Rationale and Methodology for the Use of Medical Xenon in the Complex Treatment of Pain Syndrome in Osteoarthritis: A Review. Bulletin of Rehabilitation Medicine. 2026; 25(4):105–113. https://doi.org/10.38025/2078-1962-2026-25-4-105-113 (In Russ.).

FOR CORRESPONDENCE:

Elena A. Shomina, E-mail: 9286438@mail.ru


References:

  1. Ostrowski R.P., Pucko E.B. Research of medical gases in Poland. Med Gas Res. 2013; 3: 17. https://doi.org/10.1186/2045-9912-3-17
  2. Назаров Е.И. Озоновая, ксеноновая и озоново-ксеноновая терапия. Обзор. Биорадикалы и антиоксиданты. 2016; 3(2): 50–59. [Nazarov E.I. Ozone, xenon and ozone-xenon therapy. Review. Bioradicals Antioxid. 2016; 3(2): 50–59 (In Russ.).]
  3. Gadani H., Vyas A. Anesthetic gases and global warming: Potentials, prevention and future of anesthesia. Anesth Essays Res. 2011; 5(1): 5–10. https://doi.org/10.4103/0259-1162.84171
  4. Лазарев Н.В., Люблина Е.И., Мадорская Р.Я. О наркотическом действии ксенона. Физиологический журнал СССР. 1948; 34(1): 131–134. [Lazarev N.V., Lyublina E.I., Madorskaya R.Ya. On the narcotic effect of xenon. Fiziol Zh SSSR. 1948; 34(1): 131–134 (In Russ.).]
  5. Lawrence J.H., Loomis W.F., Franklin F.C., et al. Preliminary observations on the narcotic effect of xenon with a review of values for solubilities of gases in water and oils. J Physiol. 1946; 105(3): 197–204. https://doi.org/10.1113/jphysiol.1946.sp004164
  6. Cullen S.C., Gross E.G. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951; 113(2942): 580–582. https://doi.org/10.1126/science.113.2942.580
  7. Zhai X., Chen X., Ohta S., et al. Review and prospect of the biomedical effects of hydrogen. Med Gas Res. 2014; 4(1): 19. https://doi.org/10.1186/s13618-014-0019-6
  8. Barker E. The xenon CT: a new neuro tool. RN. 1998; 61(2): 22–25.
  9. Буров Н.Е. Патогенетические основы терапии ксеноном. В кн.: Материалы третьей конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. Москва; 2012; с. 25–30. [Burov N.E. Pathogenetic basis of xenon therapy. In: Proceedings of the third conference of anesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. Moscow. 2012; pp. 25–30 (In Russ.).]
  10. Natale G., Ferrari E., Pellegrini A., et al. Main organ morphology and blood analysis after subchronic exposure to xenon in rats. Appl Cardiopulm Pathophysiol. 1998; 7: 227–233.
  11. Буров Н.Е., Потапов В.Н. Наркоз ксеноном: методические рекомендации. М.: РМАПО. 2003; с. 1–20. [Burov N.E., Potapov V.N. Xenon anesthesia: guidelines. Moscow: RMAPO. 2003; pp. 1–20 (In Russ.).]
  12. Lobo N., Ma D., Rizvi M.S., et al. Hypothermia and xenon: novel noble guardians in hypoxic-ischemic encephalopathy. J Neurosci Res. 2013; 91(4): 473–478. https://doi.org/10.1002/jnr.23185
  13. Стец В.В., Панова Н.Г., Колобаева Е.Г. Влияние ксенона на функцию внешнего дыхания у пациентов травматологического профиля. В кн.: Материалы третьей конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. Москва. 2012; с. 120–121. [Stets V.V., Panova N.G., Kolobaeva E.G. Influence of xenon on the function of external respiration in traumatological patients. In: Proceedings of the third conference of anesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. Moscow. 2012; pp. 120–121 (In Russ.).]
  14. Давыдова Н.С., Наумов С.А., Костромитина Г.Г., и др. Клинические и инструментальные методы контроля при ксеноновых ингаляциях. Вестн. Уральской мед. акад. науки. 2013; 2: 20–24. [Davydova N.S., Naumov S.A., Kostromitina G.G., et al. Clinical and instrumental methods of control during xenon inhalations. Vestn. Ural. Med. Akad. Nauki. 2013; 2: 20–24 (In Russ.).]
  15. Boomsma F., Rupreht J., Man in’t Veld A.J., et al. Haemodynamic and neurohumoral effects of xenon anaesthesia. A comparison with nitrous oxide. Anaesthesia. 1990; 45(4): 273–278. https://doi.org/10.1111/j.1365-2044.1990.tb15045.x
  16. Cantor R.S. The lateral pressure profile in membranes: a physical mechanism of general anesthesia. Biochemistry. 1997; 36(9): 2339–2344. https://doi.org/10.1021/bi9627323
  17. Miller K.W. Inert gas narcosis, the high pressure neurological syndrome, and the critical volume hypothesis. Science. 1974; 185(4154): 867–869. https://doi.org/10.1126/science.185.4154.867
  18. Wlodarczyk A., McMillan P.F., Greenfield S.A. High pressure effects in anaesthesia and narcosis. Chem Soc Rev. 2006; 35(10): 890–898. https://doi.org/10.1039/b517771p
  19. Francis M.J., Pashley R.M., Rzechowicz M. The hydrophobicity of non-aqueous liquids and their dispersion in water under degassed conditions. Curr Opin Colloid Interface Sci. 2008; 13(4): 236–244. https://doi.org/10.1016/j.cocis.2008.03.004
  20. Shatalov V.M. Mechanism of the Biological Impact of Weak Electromagnetic Fields and the In vitro Effects of Blood Degassing. Biophysics. 2012; 57(6): 808–813. https://doi.org/10.1134/S0006350912060182
  21. Крюков Е.В., Курбангалиев Р.И. и др. Применение медицинского ксенона при лечении острых и хронических болевых синдромов. Методические рекомендации. М.: ГВКГ им. Н.Н. Бурденко. 2015; 36 с. [Kryukov E.V., Kurbangaliev R.I., et al. The use of medical xenon in the treatment of acute and chronic pain syndromes. Guidelines. Moscow: Burdenko Main Military Clinical Hospital. 2015; 36 p. (In Russ.).]
  22. Давыдова Н.С., Наумов С.А., Костромитина Г.Г. и др. Кислородно-ксеноновые ингаляции в поликлинической практике. Поликлиника. 2013; (5): 44–47. [Davydova N.S., Naumov S.A., Kostromitina G.G., et al. Oxygen-xenon inhalations in outpatient practice. Poliklinika. 2013; (5): 44–47 (In Russ.).]
  23. Hoehn K., Marieb E.N. Human Anatomy & Physiology. 7th ed. San Francisco: Pearson Education. 2007; 1159 p.
  24. Белов А.В., Сокологорский С.В. Минимально-поточная анестезия ксеноном в эндоскопической гинекологии. В кн.: Материалы третьей конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. Москва. 2012; с. 22–24. [Belov A.V., Sokologorskiy S.V. Minimal-flow anesthesia with xenon in endoscopic gynecology. In: Proceedings of the third conference of anesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. Moscow. 2012; pp. 22–24 (In Russ.).]
  25. Афонина И.Ю., Мокрушина Ю.А., Павлова Р.А. и др. Влияние ксенона на эмоциональную сферу терапевтических пациентов с сопутствующей энцефалопатией различного генеза. В кн.: Материалы третьей конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. Москва. 2012; с. 97–101. [Afonina I.Yu., Mokrushina Yu.A., Pavlova R.A., et al. The effect of xenon on the emotional sphere of therapeutic patients with concomitant encephalopathy of various origins. In: Proceedings of the third conference of anesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. Moscow. 2012; pp. 97–101 (In Russ.).]
  26. Бубеев Ю.А., Бояринцев В.В., Базий Н.И. и др. Применение медицинского ксенона при лечении связанных со стрессом психических расстройств невротического уровня. Методические рекомендации. Москва. 2014; 28 с. [Bubeev Yu.A., Boyarintsev V.V., Baziy N.I., et al. The use of medical xenon in the treatment of stress-related mental disorders of the neurotic level. Guidelines. Moscow. 2014; 28 p. (In Russ.).]
  27. Лихванцев В.В. Практическое руководство по анестезиологии. М.: Медицинское информационное агентство. 1998; 288 с. [Likhvantsev V.V. Practical guide to anesthesiology. Moscow: Meditsinskoe informatsionnoe agentstvo.1998; 288 p. (In Russ.).]
  28. Буров Н.Е., Потапов В.Н., Макеев Г.Н. Ксенон в анестезиологии. М.: Пульс. 2000; 291 с. [Burov N.E., Potapov V.N., Makeev G.N. Xenon in anesthesiology. Moscow: Puls. 2000; 291 p. (In Russ.).]
  29. Ситников Е.В. Опыт применения кислородно-ксеноновых ингаляций для купирования послеоперационных болей при операции открытого синус-лифта. В кн.: Материалы третьей конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. Москва. 2012; с. 115–117. [Sitnikov E.V. Experience of using oxygen-xenon inhalations for the relief of postoperative pain during open sinus lift surgery. In: Proceedings of the third conference of anesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. Moscow; 2012; pp. 115–117 (In Russ.).]
  30. Nakata Y., Goto T., Ishiguro Y., et al. Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans. Anesthesiology. 2001; 94(4): 611–614. https://doi.org/10.1097/00000542-200104000-00013
  31. Gozhenko A.I., Gritsenyuk M.S., et al. Physiological effects of oral intake of an aqueous solution of xenon. J Health Sci. 2014; 4(7): 123–132.
  32. Каменев А.В., Степанов А.Г. Применение ксенона для лечения больных с поясничным остеохондрозом позвоночника. В кн.: Материалы третьей конференции анестезиологов-реаниматологов медицинских учреждений МО РФ. Москва. 2012; 118–120 с. [Kamenev A.V., Stepanov A.G. The use of xenon for the treatment of patients with lumbar osteochondrosis of the spine. In: Proceedings of the third conference of anesthesiologists-resuscitators of medical institutions of the Ministry of Defense of the Russian Federation. Moscow. 2012; pp. 118–120 (In Russ.).]
  33. Liu W., Khatibi N., Sridharan A., et al. Application of medical gases in the field of neurobiology. Med Gas Res. 2011; 1(1): 13. https://doi.org/10.1186/2045-9912-1-13
  34. Hawker G.A., Mian S., Kendzerska T., et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011; 63(Suppl 11): S240–S252. https://doi.org/10.1002/acr.20577
  35. Giacalone M., Abramo A., Giunta F., et al. Xenon-related analgesia: a new target for pain treatment. Clin J Pain. 2013; 29(7): 639–643. https://doi.org/10.1097/AJP.0b013e31826a64a5
  36. Nonaka K., Nakamura M., Noda M., et al. Synaptic effects of xenon on NMDA receptor-mediated response in rat spinal neuron. Neurosci Lett. 2024; 836: 137885. https://doi.org/10.1016/j.neulet.2024.137885
  37. Liu L.T., Xu Y., Tang P. Mechanistic insights into xenon inhibition of NMDA receptors from MD simulations. J Phys Chem B. 2010; 114(27): 9010–9016. https://doi.org/10.1021/jp101908w
  38. Хиновкер В.В., Веселова О.Ф., Хиновкер Е.В. и др. Лечение нейропатической боли ксеноном. Регионарная анестезия и лечение острой боли. 2022; 16(2): 151–159. [Khinovker V.V., Veselova O.F., Khinovker E.V., et al. Xenon for neuropathic pain treatment. Reg Anesth Acute Pain Manag. 2022; 16(2): 151–159 (In Russ.).]
  39. Lv H., Huang J., Zhang X., et al. Xenon ameliorates chronic post-surgical pain by regulating mitophagy in microglia and rats mediated by PINK1/Parkin pathway. PeerJ. 2024; 12: e16855. https://doi.org/10.7717/peerj.16855
  40. Yang Y.S., Wu S.H., Chen W.C., et al. Effects of xenon anesthesia on postoperative neurocognitive disorders: a systematic review and meta-analysis. BMC Anesthesiol. 2023; 23(1): 366. https://doi.org/10.1186/s12871-023-02331-6
  41. Kaufman T.J., Meloni E.G., Qrareya A.N., et al. Effects of inhaled low-concentration xenon gas on naltrexone-precipitated withdrawal symptoms in morphine-dependent mice. Drug Alcohol Depend. 2024; 255: 110967. https://doi.org/10.1016/j.drugalcdep.2024.110967
  42. Zhang H., Baby H.M., Ishihara S., et al. Extended osteoarthritis pain relief with neosaxitoxin using alginate-core polymeric microparticles. Nanoscale. 2025; 17(44): 25664–25679. https://doi.org/10.1039/d5nr02912k
  43. Ярыгин Н.В., Шомина Е.А. Применение ксенона в медицинской практике (обзор литературы). Практическая медицина. 2022; 20(4): 171–176. [Yarygin N.V., Shomina E.A. Use of xenon in medical practice (literature review). Practical medicine. 2022; 20(4): 171–176 (In Russ.).]



Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©


This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.